In this article, we will be taking a look at the 5 Best Immunology Stocks to Buy According to Hedge Funds. If you wish to see the full list, visit 8 Best Immunology Stocks to Buy According to Hedge Funds.

5. MoonLake Immunotherapeutics (NASDAQ:MLTX)

Number of Hedge Fund Holders: 48

MoonLake Immunotherapeutics (NASDAQ:MLTX) is among the best immunology stocks.

TheFly reported on May 11 that H.C. Wainwright increased its price objective on MLTX to $45 from $40 while reaffirming a Buy rating on the stock. The revision followed encouraging regulatory progress for sonelokimab, the company’s nanobody-based therapy being developed for hidradenitis suppurativa. The firm highlighted the favorable outcome of MLTX’s final pre-application discussions with the FDA regarding the program, signaling continued advancement toward potential regulatory filings and supporting confidence in the treatment’s clinical development strategy.

On May 10, MoonLake Immunotherapeutics (NASDAQ:MLTX) provided a corporate and financial update highlighting regulatory progress for sonelokimab in hidradenitis suppurativa. Following a successful pre-BLA meeting with the FDA held on April 1, the company confirmed alignment on its planned biologics license application submission strategy, proposed labeling approach, and use of data from the MIRA and VELA-TEEN studies. MoonLake stated that the BLA filing for sonelokimab is scheduled for late September 2026, with potential FDA acceptance anticipated by the end of November 2026.

The company also noted continued advancement across additional clinical programs, including Phase 3 studies in psoriatic arthritis. Financially, MLTX ended the first quarter with $357.9 million in cash, cash equivalents, and short-term marketable securities, while maintaining expected funding capacity into the end of 2027 alongside access to up to $400 million through its Hercules Capital debt agreement.

MoonLake Immunotherapeutics (NASDAQ:MLTX) is a clinical-stage biopharmaceutical company developing treatments for inflammatory skin and joint diseases. Its lead therapy, sonelokimab, uses Nanobody technology to target IL-17A and IL-17F cytokines involved in immune-related conditions.

4. Moderna, Inc. (NASDAQ:MRNA)

Number of Hedge Fund Holders: 52

Moderna, Inc. (NASDAQ:MRNA) is among the best immunology stocks to invest in.

TheFly reported earlier this month, on May 4, that UBS increased its price objective on MRNA to $45 from $36 while continuing to hold a Neutral stance on the stock. The firm pointed to several upcoming pipeline developments that could influence investor sentiment if the company delivers favorable clinical results across its programs.

More recently, on May 21, Moderna, Inc. (NASDAQ:MRNA) disclosed that its investigational mRNA influenza vaccine will undergo evaluation by an FDA advisory committee on June 18 ahead of the agency’s August 5 regulatory decision deadline. The scheduled review marks a significant step in the vaccine’s approval process and reflects renewed emphasis on external scientific assessment during regulatory evaluations.

The advisory panel meeting is expected to examine clinical evidence supporting the vaccine candidate’s safety and effectiveness before the FDA determines whether to authorize the product. The development also drew attention as advisory committee reviews had become less frequent in recent years for certain vaccine applications. Investors and industry observers are closely monitoring the outcome of the meeting, as positive feedback from the panel could strengthen confidence in Moderna’s broader respiratory vaccine pipeline and support future commercial opportunities beyond its COVID-19 franchise.

Moderna, Inc. (NASDAQ:MRNA) is a biotechnology company specializing in mRNA-based therapies and vaccines. Founded in 2010 and headquartered in Cambridge, Massachusetts, it develops treatments for infectious diseases, cancer, rare diseases, and autoimmune disorders.

3. AbbVie Inc. (NYSE:ABBV)

Number of Hedge Fund Holders: 87

AbbVie Inc. (NYSE:ABBV) is among the best immunology stocks.

TheFly reported on May 27 that ABBV announced FDA approval of DECNUPAZ (pivekimab sunirine-pvzy) for adults diagnosed with blastic plasmacytoid dendritic cell neoplasm (BPDCN), a rare and fast-progressing blood cancer with limited available therapies. The authorization was supported by findings from the Phase 1/2 CADENZA study, which evaluated the treatment’s safety and clinical activity in BPDCN patients.

Trial results showed strong and lasting responses among newly diagnosed participants, including a 69.7% composite complete response rate and a median response duration of 9.7 months. Patients with relapsed or refractory disease recorded a 15.7% composite complete response rate with a 9.2-month median duration of response. Several patients later proceeded to stem cell transplantation following treatment.

Separately, on May 22, AbbVie Inc. (NYSE:ABBV) announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use issued a favorable recommendation for Maviret, the company’s oral pangenotypic antiviral therapy for acute hepatitis C. The recommendation covers treatment for adults as well as children aged 3 years and older. ABBV stated that a final decision from the European Commission is anticipated during the third quarter of 2026. If authorized, Maviret would become approved in the European Union for both acute and chronic hepatitis C infections, potentially expanding its treatment use across a broader patient population.

AbbVie Inc. (NYSE:ABBV) is a global biopharmaceutical company and a leader in immunology. Spun off from Abbott Laboratories in 2013, it develops treatments for immune-mediated diseases across rheumatology, dermatology, and gastroenterology, including rheumatoid arthritis, psoriasis, Crohn’s disease, and ulcerative colitis.

2. Merck & Co., Inc. (NYSE:MRK)

Number of Hedge Fund Holders: 98

Merck & Co., Inc. (NYSE:MRK) is also one of the best immunology stocks to buy.

TheFly reported on May 22 that MRK announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use issued a positive recommendation supporting approval of KEYTRUDA in combination with Padcev for adults with resectable muscle-invasive bladder cancer who are not eligible for cisplatin-based chemotherapy. The CHMP opinion covers the use of KEYTRUDA, including its subcutaneous formulation, in the perioperative setting, with treatment continued after radical cystectomy.

The recommendation will now be reviewed by the European Commission, with a final decision expected in the third quarter of 2026. The decision is supported by Phase 3 KEYNOTE-905 results showing meaningful improvements in event-free survival, overall survival, and pathologic complete response compared with surgery alone.

Concurrently, on May 18, Merck & Co., Inc. (NYSE:MRK) reported that its Phase 3 TroFuse-005 study of sacituzumab tirumotecan (sac-TMT), a TROP2-directed antibody-drug conjugate developed with Kelun-Biotech, achieved both of its primary endpoints. The trial demonstrated statistically significant improvements in overall survival and progression-free survival in patients with advanced or recurrent endometrial cancer who had previously received platinum-based chemotherapy and anti–PD-1/PD-L1 therapy.

It also met a key secondary endpoint of objective response rate. These results represent the first global Phase 3 evidence showing superiority over chemotherapy in this setting and will be shared at a future medical meeting. Merck stated the safety profile remained consistent with prior studies, with no new safety concerns identified.

Merck & Co., Inc. (NYSE:MRK) is a global biopharmaceutical company with a strong focus on oncology, led by its flagship drug Keytruda. It is also expanding into immunology, developing treatments for immune-mediated inflammatory diseases.

1. Eli Lilly and Company (NYSE:LLY)

Number of Hedge Fund Holders: 132

Eli Lilly and Company (NYSE:LLY) is among the best immunology stocks.

TheFly reported on May 26 that LLY agreed to acquire Vaccine Company, Inc., a clinical-stage biotech focused on in vivo nanoparticle vaccine technology designed to mimic virus-like particle immune responses without the complex manufacturing required for traditional VLP approaches. The company’s pipeline includes multiple preclinical programs targeting viral diseases, with its lead Epstein-Barr Virus candidate advancing toward Phase 1 readiness using a five-antigen design.

The acquisition deal values Vaccine Company at up to $1.55 billion in cash, structured with an upfront payment plus additional milestone-based payouts tied to clinical and commercial progress. The technology is being explored for the prevention of EBV-related conditions, including infectious mononucleosis and potential long-term neurological and oncologic outcomes.

Separately, on May 25, Eli Lilly and Company (NYSE:LLY) reported positive Phase 1b Heart-2 study data for VERVE-102, an investigational in vivo base-editing therapy intended to permanently inactivate the PCSK9 gene in the liver to reduce LDL cholesterol after a single infusion. The study enrolled adults with heterozygous familial hypercholesterolemia or premature coronary artery disease.

Interim results from 35 participants showed a single intravenous dose produced dose-dependent declines in circulating PCSK9 protein ranging from 51% to 88%, alongside LDL-C reductions spanning 9% to 62% across dose groups. These lipid-lowering effects were sustained, with durability observed for up to 18 months after treatment, supporting prolonged therapeutic activity following one administration.

Eli Lilly and Company (NYSE:LLY) is a global pharmaceutical company focused on developing treatments in cardiometabolic diseases, oncology, immunology, and neuroscience. It is a growing leader in immunology, with a portfolio of biologic and targeted therapies for immune-mediated inflammatory conditions.

READ NEXT: 10 Best Reddit Stocks to Buy According to Billionaires and 10 Safe Stocks to Buy for the Long Term in 2026

Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.